Jan 30 (Reuters) - India's Dr Lal Path Labs (DLPA.NS), opens new tab reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its ...
Earnings call Dr. Lal PathLabs reported Q1 FY26 revenue of ₹670 crore, up 11.3% YoY, with PAT growing 24.3% to ₹134 crore. EBITDA margin held strong at 28.7%. Management reaffirmed 11–12% full-year ...
Dr Lal PathLabs on Friday announced its Q3 results, reporting a year-on-year increase in revenue while net profit declined.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results